IMMP — Immutep Limited
Is IMMP overbought or oversold? Here is the current MarketMoodz read.
Immutep Limited (IMMP) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.40. The rating moved from Overbought to Neutral on November 17, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$3.40
- Last changeMoved from Overbought to Neutral on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
Immutep Limited (IMMP) is an early‑stage immunotherapy company where value is driven primarily by clinical readouts and partnering opportunities. The company’s small‑cap status and likely limited cash runway create significant dilution and execution risk, while successful trial results or licensing deals could produce outsized upside. Expect elevated volatility tied to clinical milestones, with near‑term performance dependent on trial timelines, data quality, and capital‑raising dynamics.
Key factors
- Early‑stage immunotherapy pipeline (LAG‑3 focus) with binary clinical readouts that can reprice the equity
- Near‑term catalysts from upcoming trial data or partnering/licensing discussions that could drive upside
- Small‑cap profile with limited market capitalization and typically higher volatility/lower liquidity
- Sector environment: investor preference for large‑cap pharma may limit defensive flows into micro‑cap biotech despite risk‑on mood
- Potential strategic interest from larger pharma for novel immuno‑oncology assets increases M&A/read‑through optionality
- Convertible/debt/dilution pressures seen across biotech sector could be relevant if additional financing is required
Risks
- High clinical trial risk: negative or inconclusive data would materially reduce share value
- Financing risk and potential dilution if cash runway is short and capital markets are needed
- Competitive risk: crowded immuno‑oncology and LAG‑3 landscape with larger, better‑funded rivals
- Regulatory risk and lengthy approval pathways that can delay commercialization
- Low liquidity and high share price volatility can exacerbate moves on news or block trades
- Macro/sector rotation toward large‑cap defensive pharma could reduce investor appetite for small biotech
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for IMMP — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.